146 related articles for article (PubMed ID: 37976756)
1. Immune checkpoint inhibitors with chemotherapy for primary advanced mismatch repair-deficient endometrial cancer: A cost-effectiveness analysis.
Kim J; Lim J; Lee SW; Park JY; Suh DS; Kim JH; Kim YM; Kim DY
Gynecol Oncol; 2023 Dec; 179():106-114. PubMed ID: 37976756
[TBL] [Abstract][Full Text] [Related]
2. Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.
Dioun S; Chen L; Melamed A; Gockley A; St Clair CM; Hou JY; Khoury-Collado F; Hur C; Elkin E; Accordino M; Hershman DL; Wright JD
BJOG; 2023 Jan; 130(2):214-221. PubMed ID: 36330672
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.
Liu K; Zhu Y; Zhou Y; Zhang Y; Zhu H
Gynecol Oncol; 2022 Sep; 166(3):582-588. PubMed ID: 35781166
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy.
Dioun S; Chen L; De Meritens AB; St Clair CM; Hou JY; Khoury-Collado F; Pua T; Hershman DL; Wright JD
Gynecol Oncol; 2024 Mar; 182():70-74. PubMed ID: 38262241
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer.
Huo G; Song Y; Chen P
J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38606826
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer.
You M; Zeng X; Zhang J; Huang Y; Zhang Y; Cai Z; Hu Y
Front Immunol; 2023; 14():1267322. PubMed ID: 37731489
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer.
Riedinger CJ; Barrington DA; Nagel CI; Khadraoui WK; Haight PJ; Tubbs C; Backes FJ; Cohn DE; O'Malley DM; Copeland LJ; Chambers LM
Gynecol Oncol; 2024 Mar; 183():78-84. PubMed ID: 38554477
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden.
Ralph L; Young K; Upadhyay N; Prabhu VS; Ljungcrantz C; Massaad R; Xu R; Giertz A; Merchant A; Orlowski R; Duska L
J Med Econ; 2024; 27(1):483-491. PubMed ID: 38470404
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.
Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R
J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
Ackroyd SA; Huang ES; Kurnit KC; Lee NK
Gynecol Oncol; 2021 Aug; 162(2):249-255. PubMed ID: 34103196
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
Shi Y; Chen J; Shi B; Liu A
Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis.
Feng M; Chen Y; Yang Y; Li Q
Front Public Health; 2022; 10():881034. PubMed ID: 35619813
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib plus pembrolizumab in the patients with advanced previously treated endometrial cancer: A cost-effectiveness analysis in the United States and in China.
Liao X; Wu Y; Lin D; Gu D; Luo S; Huang X; Xu X; Weng X; Lin S
J Obstet Gynaecol Res; 2024 May; 50(5):881-889. PubMed ID: 38485235
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.
Zhu C; Han G; Wu B
BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
Barrington DA; Haight PJ; Calhoun C; Tubbs C; Cohn DE; Bixel KL
Gynecol Oncol; 2021 Sep; 162(3):626-630. PubMed ID: 34148720
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China.
Zheng Z; Yang L; Xu S; Zhu H; Cai H
Front Pharmacol; 2022; 13():944931. PubMed ID: 36249813
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
Liu T; Liu S; Guan S; Tai Y; Jin Y; Dong M
J Chemother; 2023 Dec; 35(8):745-752. PubMed ID: 36591729
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of pembrolizumab in patients with treatment-refractory metastatic colorectal cancer in Japan.
Sugiura K; Hiratsuka H; Oshima G; Aiko S
Jpn J Clin Oncol; 2023 Jul; 53(8):691-697. PubMed ID: 37259600
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
Zhan M; Xu T; Zheng H; He Z
Front Public Health; 2022; 10():790225. PubMed ID: 35309225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
